2.2. Study Design
overweight
OBESE
A double-blind, placebo-controlled, randomized, parallel design was conducted on overweight and obese individuals between March 2021 and January 2022 at Chulalongkorn University in Bangkok, Thailand. The total sample size required for this study was calculated to be In the current study, a total of 80 individuals were enrolled for screening, but only 72 of them successfully completed the screening process. Participants were randomly assigned to either a placebo (